Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.49 |
| ▸ | GMPS | P49915 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.47 |
| ▸ | PI4KA | P42356 | 2/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.47 |
| ▸ | SLC28A1 | O00337 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | GAPDH | P04406 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | STAT6 | P42226 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27765322 | 0.93 | ADORA3 (0.48) | ADORA3ADORA2AGMPSSLC29A1PI4KA | |
| SCHEMBL13269151 | 0.93 | ADORA2A (0.48) | ADORA3ADORA2AGMPSSLC29A1PI4KA | |
| SCHEMBL62485 | 0.93 | ADORA3 (0.48) | ADORA3ADORA2AGMPSSLC29A1PI4KA | |
| SCHEMBL13269127 | 0.92 | ADORA3 (0.48) | ADORA3ADORA2AGMPSSLC29A1PI4KA | |
| SCHEMBL4541363 | 0.92 | ADORA3 (0.48) | ADORA3ADORA2AGMPSSLC29A1PI4KA | |
| SCHEMBL13269086 | 0.92 | ADORA3 (0.48) | ADORA3ADORA2AGMPSSLC29A1PI4KA | |
| SCHEMBL622587 | 0.92 | ADORA3 (0.49) | ADORA3ADORA2AGMPSSLC29A1PI4KA | |
| SCHEMBL447209 | 0.90 | ADORA3 (0.48) | ADORA3ADORA2AGMPSSLC29A1PI4KA | |
| SCHEMBL13269077 | 0.89 | ADORA3 (0.46) | ADORA3ADORA2AGMPSSLC29A1PI4KA | |
| SCHEMBL14696729 | 0.89 | ADORA3 (0.46) | ADORA3ADORA2AGMPSSLC29A1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-02-21 | — | — | US | claimed |
| EP-2511283-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2012-10-17 | — | — | EP | claimed |
| US-10174033-B2 | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2019-01-08 | — | — | US | disclosed |
| CN-102812033-B | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2015-11-25 | — | — | CN | disclosed |
| EP-2295434-B1 | Substituted 8-heteroaryl xanthines | DOGWOOD PHARMACEUTICALS INC (US) | 2015-09-30 | — | — | EP | disclosed |
| EP-2029143-B1 | SUBSTITUTED 8-[6-AMINO-3-PYRIDYL]XANTHINES | DOGWOOD PHARMACEUTICALS INC (US) | 2015-07-08 | — | — | EP | disclosed |
| CN-104382924-A | N6-substituted adenosine derivative and N6-substituted adenine derivative and application thereof | INST MATERIA MEDICA CAMS | 2015-03-04 | — | — | CN | disclosed |
| EP-1658291-B1 | SUBSTITUTED 8-HETEROARYL XANTHINES | DOGWOOD PHARMACEUTICALS INC (US) | 2013-10-02 | — | — | EP | disclosed |
| CN-103145712-A | Substituted 8-[6-amino-3-pyridyl]xanthenes | PGXHEALTH LLC | 2013-06-12 | — | — | CN | disclosed |
| US-8420813-B2 | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines | DOGWOOD PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-02-21 | — | — | US | disclosed |
| CN-1894250-A | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS LLC (US) | 2007-01-10 | — | — | CN | disclosed |
| WO-2006091898-A2 | PYRAZOLYL SUBSTITUTED XANTHINES | ADENOSINE THERAPEUTICS, LLC (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006091936-A2 | METHODS FOR THE SYNTHESIS OF UNSYMMETRICAL CYCLOALKYL SUBSTITUTED XANTHINES | ADENOSINE THERAPEUTICS, LLC (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1658291-A2 | SUBSTITUTED 8-HETEROARYL XANTHINES | Adenosine Therapeutics, LLC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20050065341-A1 | Substituted 8-heteroaryl xanthines | ALLERGAN SALES, LLC | 2005-03-24 | — | — | US | disclosed |
| WO-2005021548-A2 | SUBSTITUTED 8-HETEROARYL XANTHINES | ADENOSINE THERAPEUTICS, LLC (US) | 2005-03-10 | — | — | WO | disclosed |
| US-6545002-B1 | Treating asthma, diarrhea, insulin resistance, diabetes, ischemia/reprefusion injuries, diabetic retinopathy or hyperbaric oxygen-induced retinopathy | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2003-04-08 | — | — | US | disclosed |
| EP-1192158-A2 | SUBSTITUTED 8-PHENYLXANTHINES USEFUL AS ANTAGONISTS OF A 2B? ADENOSINE RECEPTORS | University of Virginia Patent Foundation (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000073307-A2 | SUBSTITUTED 8-PHENYLXANTHINES USEFUL AS ANTAGONISTS OF A2B ADENOSINE RECEPTORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065341-A1 | Substituted 8-heteroaryl xanthines | ADORA2B, ADORA2A, ADORA3 | ADORA3 3/4885ADORA2A 2/4885GMPS 1728/4885 |
| US-10174033-B2 | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA2A 1/4885GMPS 866/4885 |
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA2A 1/4885GMPS 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.